Results 271 to 280 of about 950,400 (402)

SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia. [PDF]

Clin Transl Med
Mancini M, De Santis S, Monaldi C, Castagnetti F, Iezza M, Iurlo A, Cattaneo D, Galimberti S, Cerrano M, Capodanno I, Bonifacio M, Rossi M, Agostinelli C, Meggendorfer M, Haferlach T, Cavo M, Gugliotta G, Soverini S.   +17 more
europepmc   +1 more source

Specific receptors for phorbol diesters on freshly isolated human myeloid and lymphoid leukemia cells: comparable binding characteristics despite different cellular responses [PDF]

, 1984
Goodwin Bj, Moore Jo, JB Weinberg
openalex   +1 more source

Molecular Minimal Residual Disease in Acute Myeloid Leukemia

New England Journal of Medicine, 2018
M. Jongen‐Lavrencic, T. Grob, Diana Hanekamp, F. Kavelaars, A. A. Al Hinai, A. Zeilemaker, Claudia A. J. Erpelinck-Verschueren, P. Gradowska, R. Meijer, J. Cloos, B. Biemond, C. Graux, M. van Marwijk Kooy, M. Manz, T. Pabst, J. Passweg, V. Havelange, G. Ossenkoppele, M. Sanders, G. Schuurhuis, B. Löwenberg, P. Valk   +21 more
semanticscholar   +1 more source

Enhancer‐dependent gene regulation in space, time, and malignancies

International Journal of Cancer, EarlyView.
Abstract Control of cell‐type‐specific gene activation requires the coordinated activity of distal regulatory elements, including enhancers, whose inputs must be temporally integrated. Dysregulation of this regulatory capacity, such as aberrant usage of enhancers, can result in malignant transformation of cells.
Belinda Blum, Victoria Dachtler, Angelika Feldmann   +2 more
wiley   +1 more source

Mapping of Functional Metabolic Phenotypes in Acute Myeloid Leukemia. [PDF]

Cancer Med
Dyrstad S, Hatfield KJ, Stigen E, Brattås MK, Tronstad KJ, Reikvam H.   +5 more
europepmc   +1 more source

Preferential response of acute myeloid leukemias with translocation involving chromosome 17 to human recombinant granulocyte colony- stimulating factor [PDF]

, 1988
MJ Pébusque, Marina Lafage, M Lopez, P Mannoni   +3 more
openalex   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers. [PDF]

Front Oncol
Sicuranza A, Cavalleri A, Bernardi S.
europepmc   +1 more source

The effects of dexamethasone and tetradecanoyl phorbol acetate on plasminogen activator release by human acute myeloid leukemia cells [PDF]

, 1983
EL Wilson, P Jacobs, EB Dowdle
openalex   +1 more source

Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

New England Journal of Medicine, 2017
A. Hochhaus, R. Larson, F. Guilhot, J. Radich, S. Branford, T. Hughes, M. Baccarani, M. Deininger, F. Cervantes, Satoko Fujihara, C. Ortmann, H. Menssen, H. Kantarjian, S. O’Brien, B. Druker   +14 more
semanticscholar   +1 more source